Dr Allen’s Therapeutic Devices Should be Implemented in the Healthcare System for the Treatment of Chronic Noncancerous Prostate and Kidney Diseases Saving People’s Well-Being and Money

Abstract

Background: Innovative thermobalancing therapy (TT) with Dr Allen's therapeutic device (DATD) treats affected organs by the energy of one's own body. 10 years empirical evidence has shown that the use of DATD helps to recover from chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and benign prostatic hyperplasia (BPH), and to dissolve kidney stones. Moreover, the cost of DATD compares favourably with the cost of conventional treatments. Objectives: The purpose of this study is to point to the introduction of TT from DATD to the Primary Health Care system. Methods and Results: Two clinical trials observed dynamics of urinary symptoms by International Prostate Symptom Score (IPSS), quality of life (QoL), ultrasound prostate volume (PV mL) and uroflowmetry (maximum flow rate, Qmax mL/s) in men with BPH and chronic prostatitis. These trials have explored that TT with DATD reduced: prostate volume from 45 mL to 31 mL (P < 0.001) and, consequently, lower urinary tract symptoms, from 14.2 to 4.9 (P < 0.001) in the treatment group 124 patients with BPH; and pain score, from 10.38 to 3.58 (P < 0.001), and decrease of prostate volume from 31 mL to 27 mL (P < 0.001) in the treatment group of 45 men with CP/CPPS. The QoL improved in both treatment groups significantly. In the control groups: in 124 men with BPH in watchful waiting, and in 45 men with chronic prostatitis on standard treatment, no significant difference in parameters was observed. 10 years empirical evidence showed that DATD treats both kidneys simultaneously, dissolving kidney stones, despite their size and type. Conclusions:The outcomes of clinical studies and empirical evidence demonstrated the high effectiveness of TT, which was prescribed as mono-therapy. This therapy is side effects free. It is easy to use Dr Allen's device, which is a class 1 medical device that doesn't require involvement of a notified body. Therefore, TT with DATD should be implemented in the primary health care system as a self-managing treatment for chronic diseases.

The at-home delivery of treatment for benign prostate enlargement and chronic prostatitis enabled by Dr Allen’s Device is a valuable healthcare innovation during a pandemic

“…Men troubled by BPE and CP/CPPS can benefit from the effective prostate treatment with DATD in the safety of their home [23], avoiding unnecessary visits to clinics and hospitals and so minimising the risks of contracting coronavirus COVID-19 and passing it on to others. Therefore, TT with DATD should be used by healthcare providers for the management of BPE and CP/CPPS, particularly in older men [24]. The use of DATD can also reduce the burden of treating these prostate diseases on healthcare systems.…”